Navigation Links
Instrumentation Laboratory Achieves Record Sales in 2009
Date:5/5/2010

BEDFORD, Mass., May 5 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced total worldwide sales in 2009 of euro 425.3M ($586.4M USD).  This represents 11.2% growth v. previous year in current, and 13.2% in local currencies.  In the Company's two major business segments, Critical Care and Hemostasis Diagnostics, worldwide growth in local currencies was 13.2% and 12.4%, respectively.

"In spite of the major economic downturn, 2009 was a highly successful year for IL," said Josep Manent, Chief Executive Officer at IL.  "Unlike many of our competitors, we were able to achieve significantly greater growth than is typical in a positive economy."  

Contributing to IL's success in 2009 was a continuous stream of innovative product offerings.  Sales of their flagship Critical Care offering , the GEM Premier 4000 analyzer, grew considerably throughout the world due to its ease of use and its Intelligent Quality Management (iQM®) automated quality assurance system which enhances patient safety and ensures optimal test results.  The launch of the new Total Bilirubin assay on the GEM Premier 4000 in Europe, in addition to key new information management enhancements to their GEMweb® Plus Custom Connectivity offering, further propelled its success.  Additionally, IL successfully commercialized the GEM Premier 3500 analyzer with iQM in early 2009.

On the Hemostasis side, sales of the ACL TOP® Family of Testing Systems, offering "Testing Process Automation" for enhanced efficiency, grew significantly throughout the world, led by the ACL TOP 500 for mid-size labs.  IL also expanded its instrument offering with the launch of the new ACL TOP 700 LAS, designed to meet the needs of highly automated laboratory systems.  For the past seven years, the comprehensive HemosIL® line of reagents has consistently dominated the market with the most sophisticated assays for the diagnosis of disease and monitoring of anticoagulant therapy, and in 2009, IL continued this trend.  The introduction of several key new assays (e.g., Liquid Heparin), obtaining FDA-clearance for the exclusion of VTE on its D-Dimer HS 500 assay, and the worldwide launch of the Xpert® HemosIL FII & FV assay,  solidified IL's position as a leader and innovator in Hemostasis testing solutions.  

"For several years, we have maintained double digit growth and in 2009, facing challenging macroeconomic conditions, we successfully continued this trend," said Ramon Benet, Vice President of Worldwide Marketing, US Sales and Service at IL.  "Our organic growth is a testament to the confidence our customers place in our products and services; and, to the quality of our products, our people and our strategy."

IL's success in 2009 is visible in its outstanding above-market level of growth, not only in mature markets, but also in new territories, such as China and Latin America.  This growth also triggered the acquisition of new facilities in the US, to meet the expanding Manufacturing and R&D demands.  

Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories.  The company's product lines include critical care systems, hemostasis systems and information management systems.  IL's GEM® product offerings, part of the critical care line, include the new GEM Premier 3500 with Intelligent Quality Management (iQM®), GEM Premier™ 4000 analyzer, GEMweb Plus Custom Connectivity, and the GEM PCL Plus, a portable coagulation analyzer.  IL's hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the ACL TOP, the new ACL TOP LAS and the ACL TOP 500 CTS.  IL also offers the new ACL AcuStar™, ACL ELITE® and ELITE PRO, other hemostasis analyzers and the HemosIL® line of reagents.  IL is based in Bedford, Massachusetts.

The Instrumentation Laboratory logo, GEM, GEMweb, iQM, HemosIL, ACL TOP, ACL ELITE, and ACL AcuStar are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions.  Xpert is a registered trademark of Cepheid.  All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.


'/>"/>
SOURCE Instrumentation Laboratory
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Patient-Specific Surgical Instrumentation Expedites Total Knee Replacement Procedures
2. Instrumentation Laboratory Receives 510(K) Clearance From FDA and Canadian License for HemosIL(R) D-Dimer HS 500 Assay
3. Amerinet Awards Contract to Instrumentation Laboratory for Critical Care Portfolio
4. Instrumentation Laboratory Installs 2000th ACL TOP(R) System
5. Instrumentation Laboratory Receives FDA Clearance for HemosIL RecombiPlasTin 2G Assay
6. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China
9. Health Diagnostic Laboratory Inc. Announces New Preventative Model to Chronic Disease Management
10. Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey
11. Enigma Diagnostics Showcases Its Unique Fully Automated rtPCR Based ML (Mini-Laboratory) Instrument For Point-of-Care Testing at MEDICA 2009 In Dusseldorf, Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , February 20, 2017 According to a new ... Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, ... by MarketsandMarkets, The market is projected to reach USD 52.37 Billion by ... during the forecast period. Continue Reading ... ...
(Date:2/20/2017)...   Alberty   Drugs , a ... has announced a significant shift in focus by ... to servicing local Veteran Affairs Centers (VA) and other ... increased need to secure cost effective treatments for their ... for their goods & services. "The opportunity ...
(Date:2/20/2017)... , February 20, 2017 Acute, Chronic and ... expected to grow at a CAGR of 7% from 2016-2021 and CAGR ... CAGR of 6% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business opportunities ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... ... to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up ... facilitated by the Pepin Family Foundation. , “We greatly appreciate this gift from ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette ... the Pet Life Radio network. The episode, which was posted this week, features ... what factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... foundational and sustainable systems change designed to further positively impact the health and ... of Trustees has long considered it our duty to seriously consider releasing our ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action ... Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ... action (CA) and preventive action (PA)? , The methods share techniques and tools ...
Breaking Medicine News(10 mins):